Cencora, Inc. $COR Position Boosted by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 9.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 9,440 shares of the company’s stock after buying an additional 779 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Cencora were worth $2,830,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Price T Rowe Associates Inc. MD lifted its position in shares of Cencora by 8.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after purchasing an additional 787,858 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Cencora by 7.2% during the first quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock worth $1,507,599,000 after purchasing an additional 363,402 shares during the last quarter. Boston Partners lifted its position in shares of Cencora by 8.1% during the first quarter. Boston Partners now owns 5,411,193 shares of the company’s stock worth $1,505,984,000 after purchasing an additional 404,093 shares during the last quarter. Invesco Ltd. lifted its position in shares of Cencora by 42.1% during the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Cencora by 9.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock worth $475,890,000 after purchasing an additional 154,311 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on COR. Wells Fargo & Company increased their price objective on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the company an “equal weight” rating in a research note on Wednesday, July 16th. Finally, Jefferies Financial Group raised their price target on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research note on Monday, June 30th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and an average price target of $311.25.

Cencora Trading Up 0.0%

Cencora stock opened at $302.83 on Friday. The firm has a 50 day simple moving average of $293.24 and a 200-day simple moving average of $285.74. Cencora, Inc. has a 12-month low of $218.65 and a 12-month high of $309.35. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The stock has a market capitalization of $58.71 billion, a PE ratio of 31.16, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm had revenue of $80.66 billion during the quarter, compared to analyst estimates of $80.34 billion. During the same quarter last year, the business posted $3.34 EPS. The company’s revenue was up 8.7% on a year-over-year basis. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 22.63%.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 4,968 shares of Cencora stock in a transaction on Friday, July 18th. The shares were sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the completion of the sale, the chief executive officer owned 42,351 shares of the company’s stock, valued at $12,455,852.61. This trade represents a 10.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the firm’s stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total transaction of $4,266,543.26. Following the transaction, the chairman owned 309,913 shares in the company, valued at $90,702,237.71. This represents a 4.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,125 shares of company stock valued at $9,993,789 in the last three months. Company insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.